# Direct current stimulation induced reduction in α-synuclein in primary neurons: targeting Parkinson’s disease

**Authors:** Sophie Bechkos, Scott D Ryan, Alysia Ross, Hongyu Sun, Shawn Hayley

PMC · DOI: 10.1093/braincomms/fcag065 · Brain Communications · 2026-03-04

## TL;DR

This study shows that direct current stimulation can reduce harmful alpha-synuclein buildup in neurons linked to Parkinson's disease.

## Contribution

The study demonstrates that direct current stimulation reduces alpha-synuclein aggregation in primary neurons, a novel finding for Parkinson’s disease treatment.

## Key findings

- Direct current stimulation reduced both wild-type and A53T alpha-synuclein aggregation in neurons.
- DCS increased neuronal viability and promoted clearance of intracellular alpha-synuclein.
- Extracellular alpha-synuclein levels increased, suggesting enhanced neuronal activity and clearance.

## Abstract

Targeted electrical approaches to the treatment for Parkinson’s disease include deep brain stimulation, which is effective for core motor symptoms, such as essential tremor. Interestingly, treating comorbid depressive symptoms in Parkinson’s disease, using electroconvulsive therapy, also appears to help motor disability. But it is unclear whether such electrical strategies have any impact on the underlying disease processes of Parkinson’s disease. Since aggregation of misfolded alpha-synuclein fibrils is a pathological hallmark of Parkinson’s disease, this may be an important therapeutic target. To this end, we presently assessed whether direct current stimulation (DCS) of cortical neurons that were seeded with wild-type or A53T alpha-synuclein mutant pre-formed fibrils (PFFs) would reduce their aggregation. We found that both wild-type and A53T alpha-synuclein PFFs readily induced alpha-synuclein aggregation in primary cortical neurons and this effect was more pronounced at embryonic Day 17 (E17), compared to less mature E14-derived neurons. We did find that DCS time dependently reduced alpha-synuclein accumulation (phosphorylated and aggregate forms) within neurons and increased neuronal viability. Increased extracellular alpha-synuclein levels suggest that the DCS induced an increase in neuronal activity causing the clearance of the intracellular alpha-synuclein. These data have implications for non-invasive neuromodulation strategies to lower alpha-synuclein burden and possibly correct aberrant neuronal firing in Parkinson’s disease and other alpha-synucleinopathies.

This study found neuromodulation, by direct current stimulation (DCS) applied to primary neurons, disrupted the aggregation of the Parkinson’s disease linked, misfolded α-synuclein protein. Indeed, DCS promoted intracellular alpha-synuclein clearance and increased neuronal survival. These findings support electrical neuromodulation as a means of reducing pathological α-synuclein load.

Graphical Abstract

## Linked entities

- **Diseases:** Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Genes:** MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, GFAP (glial fibrillary acidic protein) [NCBI Gene 2670] {aka ALXDRD}, BECN1 (beclin 1) [NCBI Gene 8678] {aka ATG6, VPS30, beclin1}, GRM5 (glutamate metabotropic receptor 5) [NCBI Gene 2915] {aka GPRC1E, MGLUR5, PPP1R86, mGlu5}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}, MAP2 (microtubule associated protein 2) [NCBI Gene 4133] {aka MAP-2, MAP2A, MAP2B, MAP2C}, KLK6 (kallikrein related peptidase 6) [NCBI Gene 5653] {aka Bssp, Klk7, PRSS18, PRSS9, SP59, hK6}, PLG (plasminogen) [NCBI Gene 5340] {aka HAE4}, PDCD6IP (programmed cell death 6 interacting protein) [NCBI Gene 10015] {aka AIP1, ALIX, DRIP4, HP95, MCPH29}, MAP1LC3A (microtubule associated protein 1 light chain 3 alpha) [NCBI Gene 84557] {aka ATG8E, LC3, LC3A, MAP1ALC3, MAP1BLC3}, SNCA (synuclein alpha) [NCBI Gene 6622] {aka NACP, PARK1, PARK4, PD1}
- **Diseases:** essential tremor (MESH:D020329), Lewy (MESH:D018827), depressive symptoms (MESH:D003866), motor disability (MESH:D009069), alpha-synucleinopathies (MESH:D000080874), impairments in mood, sleep and olfaction (MESH:D000857), psychiatric illness (MESH:D001523), Parkinson's disease (MESH:D010300), LB (MESH:D020961), synaptic dysfunction (MESH:C536122), motor deficits (MESH:D009461), cytotoxicity (MESH:D064420), bradykinesia (MESH:D018476), rigidity (MESH:D009127), tremors (MESH:D014202), behavioural deficits (MESH:D001289), motor (MESH:D000068079), neuronal aggregation (MESH:D009410), ischaemic (MESH:D018917)
- **Chemicals:** Di-4-ANEPPS (MESH:C050019), MgSO4 (MESH:D008278), Alexa Fluorophore (-), F4 (MESH:C006011), Pen (MESH:C058388), streptomycin (MESH:D013307), calcium (MESH:D002118), KCl (MESH:D011189), PBS (MESH:D007854), ethanol (MESH:D000431), ice (MESH:D007053), Triton X (MESH:D017830), penicillin (MESH:D010406), rapamycin (MESH:D020123), AF3 (MESH:C014252), NAHCO3 (MESH:D017693), CO2 (MESH:D002245), PFA (MESH:C003043), AgCl (MESH:C037548), Glutamax (MESH:C054122), NDM (MESH:C052821), DAPI (MESH:C007293), picrotoxin (MESH:D010852), PBB (MESH:D011075), rotenone (MESH:D012402), glucose (MESH:D005947), NaCL (MESH:D012965), HEPES (MESH:D006531), Voltage (MESH:C069547), K+ (MESH:D011188), L-DOPA (MESH:D007980), trypan blue (MESH:D014343), Ag (MESH:D012834), CaCl2 (MESH:D002122)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** A53T
- **Cell lines:** SH-SY5Y — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0019), C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12993712/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12993712/full.md

## References

55 references — full list in the complete paper: https://tomesphere.com/paper/PMC12993712/full.md

---
Source: https://tomesphere.com/paper/PMC12993712